The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases

Tsutsumi, Tsubasa; Nakano, Dan; Hashida, Ryuki; Sano, Tomoya; Kawaguchi, Machiko; Amano, Keisuke; Kawaguchi, Takumi

doi:10.3390/nu15051123

Cited by 7 publications

(8 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous cross-sectional analysis by Miao et al studied the relationship between lung function parameters and fibrosis severity in metabolic associated fatty liver disease (MAFLD) patients and found an independent association between MAFLD and impaired pulmonary function, aligning with our findings 31 . Tsutsumi et al also found MAFLD to be an independent factor for COPD, suggesting a link via low-grade inflammation 32 . Another study investigating non-alcoholic fatty liver disease (NAFLD) prevalence and severity in patients with COPD showed a substantial prevalence of steatosis, NASH, and fibrosis, and identified obesity and insulin resistance as key contributing factors 18 .…”

Section: Discussionmentioning

confidence: 96%

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Zheng,

Liu,

Zeng

et al. 2024

Sci Rep

View full text Add to dashboard Cite

With high prevalence and substantial mortality, metabolic dysfunction-associated steatotic liver disease and chronic obstructive pulmonary disease (COPD) are significant public health concerns. Utilizing a large, population-based dataset from the National Health and Nutrition Examination Survey, our study probes the relationship between COPD prevalence and hepatic steatosis and fibrosis, as measured by Vibration-Controlled Transient Elastography. We analyzed data from 693 individuals with COPD and 7229 without. Through weighted multivariate logistic regression analysis, a restricted cubic spline curve, and threshold effect analysis, we investigated the correlation between the severity of hepatic steatosis and fibrosis and the presence of COPD. Our findings revealed a positive correlation between the controlled attenuation parameter (CAP) and COPD prevalence [OR = 1.03 (95% CI 1.01, 1.05)], even after multivariate adjustment. Furthermore, we observed a U-shaped association between CAP and COPD, where the inflection point, CAP value of 264.85 dB/m, corresponded to the lowest COPD prevalence. Our study emphasizes a substantial and complex link between hepatic steatosis and COPD. These findings urge healthcare professionals to factor liver health into COPD management and prompt further exploration into the underlying mechanisms. This could pave the way for the development of improved prevention and treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 96%

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Zheng,

Liu,

Zeng

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…MAFLD is part of a complex, multi-organic set of disorders, rather than merely a liver condition. 27 It is fueled by intricate gene-environment interactions, creating a dysfunctional metabolic medium with a range of outcomes. 28 Based on the proposed criteria, MAFLD is diagnosed when patients with hepatic steatosis meet one or more of the following three criteria: Overweight or obese, T2DM, or signs of metabolic dysregulation (Increased waist circumference, high blood pressure, low HDL cholesterol levels, hypertriglyceridemia, impaired fasting plasma glucose, IR, and chronic subclinical inflammation are at least two of the risk factors.)…”

Section: Introductionmentioning

confidence: 99%

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

Ding,

Deng,

Yang

et al. 2023

DMSO

View full text Add to dashboard Cite

Obesity,and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically to increase the risk of adverse clinical outcomes (both hepatic and extrahepatic). Type 2 diabetes mellitus (T2DM) is the most important risk factor for rapid progression of steatohepatitis and advanced fibrosis. Conversely, the later stages of MAFLD are associated with an increased risk of T2DM incident. According to the proposed criteria, MAFLD is diagnosed in patients with liver steatosis and in at least one in three: overweight or obese, T2DM, or signs of metabolic dysregulation if they are of normal weight. However, the clinical classification and correlation between obesity and MAFLD is more complex than expected. In addition, treatment for obesity and MAFLD are associated with a reduced risk of T2DM, suggesting that liver-based treatments could reduce the risk of developing T2DM. This review describes the clinical classification of obesity and MAFLD, discusses the clinical features of various types of obesity and MAFLD, emphasizes the role of visceral obesity and insulin resistance (IR) in the development of MAFLD,and summarizes the existing treatments for obesity and MAFLD that reduce the risk of developing T2DM.

show abstract

“…Multiorgan crosstalk plays a vital role in the development and advancement of various liver diseases, including NAFLD and alcohol-associated liver disease (ALD) [ 6 , 7 ]. Various organs, including the heart, kidneys, intestines, lungs, and pancreas, interact with the liver through complex signaling pathways and molecular mediators [ 8 ]. This crosstalk is mediated by factors such as hepatokines, myokines, extracellular vesicles, and immune cells, with dysfunctional crosstalk leading to multiorgan diseases and complications [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk

Yang,

Song

2023

Nutrients

View full text Add to dashboard Cite

Metabolism-associated fatty liver disease (MAFLD) is a multifaceted disease that involves complex interactions between various organs, including the gut and heart. It is defined by hepatic lipid accumulation and is related to metabolic dysfunction, obesity, and diabetes. Understanding the intricate interplay of the gut–liver–heart crosstalk is crucial for unraveling the complexities of MAFLD and developing effective treatment and prevention strategies. The gut–liver crosstalk participates in the regulation of the metabolic and inflammatory processes through host–microbiome interactions. Gut microbiota have been associated with the development and progression of MAFLD, and its dysbiosis contributes to insulin resistance, inflammation, and oxidative stress. Metabolites derived from the gut microbiota enter the systemic circulation and influence both the liver and heart, resulting in the gut–liver–heart axis playing an important role in MAFLD. Furthermore, growing evidence suggests that insulin resistance, endothelial dysfunction, and systemic inflammation in MAFLD may contribute to an increased risk of cardiovascular disease (CVD). Additionally, the dysregulation of lipid metabolism in MAFLD may also lead to cardiac dysfunction and heart failure. Overall, the crosstalk between the liver and heart involves a complex interplay of molecular pathways that contribute to the development of CVD in patients with MAFLD. This review emphasizes the current understanding of the gut–liver–heart crosstalk as a foundation for optimizing patient outcomes with MAFLD.

show abstract

The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases

Cited by 7 publications

References 82 publications

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk

Contact Info

Product

Resources

About